Next Generation Sequencing Market Size, Share, Growth, and Industry Analysis, By Type (Ion semiconductor sequencing,Sequencing by the synthesis (SBS),Nanopore sequencing,Single-molecule real-time (SMRT) sequencing), By Application (Biotechnology and Pharmaceutical Companies,Research Centres,Hospitals & Clinics,Others), Regional Insights and Forecast to 2035

Next Generation Sequencing Market Overview

The global Next Generation Sequencing Market is forecast to expand from USD 24524.94 million in 2026 to USD 29155.25 million in 2027, and is expected to reach USD 116311 million by 2035, growing at a CAGR of 18.88% over the forecast period.

The Next Generation Sequencing (NGS) market has transformed genomic research and clinical diagnostics by offering faster, scalable, and cost-efficient sequencing solutions. In 2024, more than 20 billion DNA bases per day are processed globally using high-throughput sequencing systems, a number that has grown by over 350% since 2015. Sequencing costs have dropped dramatically from USD 100,000 per genome in 2001 to less than USD 600 per genome in 2023, allowing broader adoption across research institutes, hospitals, and pharmaceutical organizations. More than 70% of oncology-related genomic studies worldwide utilize NGS platforms for variant detection, mutation analysis, and precision oncology initiatives.

The United States dominates the Next Generation Sequencing market with more than 45% of the global installations of sequencing platforms concentrated in the country. Over 800 academic research centers, 500 hospitals, and 250 biotech firms in the U.S. actively deploy NGS for clinical diagnostics and research applications. Federal funding programs, such as the National Human Genome Research Institute (NHGRI), have invested more than USD 3 billion cumulatively into sequencing projects since 2010, significantly accelerating innovation.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 68% of adoption growth is fueled by clinical diagnostics, with oncology accounting for 42% of the share.
• Major Market Restraint: 54% of laboratories cite high infrastructure and operational costs as primary barriers to adoption.
• Emerging Trends: 61% of sequencing applications are shifting toward personalized medicine, while 39% focus on infectious disease surveillance.
• Regional Leadership: North America accounts for 45% of the market, Europe 27%, Asia-Pacific 22%, and the Middle East & Africa 6%.
• Competitive Landscape: Illumina holds 48% market share, Thermo Fisher Scientific 24%, while Oxford Nanopore Technologies accounts for 12%.
• Market Segmentation: Sequencing by synthesis leads with 52% usage, followed by ion semiconductor sequencing at 23%, nanopore at 15%, and SMRT at 10%.
• Recent Development: 43% of innovations since 2022 have focused on portable sequencers, while 37% emphasize data analysis software.

Next Generation Sequencing Market Latest Trends

The Next Generation Sequencing market is witnessing significant technological transformations with the integration of artificial intelligence and cloud-based bioinformatics solutions. More than 70% of laboratories worldwide now leverage AI-powered analysis for variant interpretation, reducing turnaround times by over 60% compared to 2018.

Additionally, the market is experiencing rapid growth in liquid biopsy testing, with more than 1.2 million liquid biopsy samples processed annually using NGS platforms. The integration of NGS into non-invasive prenatal testing (NIPT) has expanded substantially, accounting for over 35% of global prenatal testing volumes in 2023.

Next Generation Sequencing Market Dynamics

DRIVER

"Rising demand for pharmaceuticals."

The increasing demand for pharmaceuticals drives significant adoption of NGS in drug discovery and development. More than 65% of pharmaceutical companies utilize sequencing technologies for biomarker identification, genetic screening, and precision drug design. In 2023, over 1,000 active drug development projects globally incorporated sequencing-based genomic analysis, reflecting its vital role in improving therapeutic outcomes. The rise of biologics and targeted therapies is further strengthening this demand, with sequencing reducing research timelines by 40% compared to traditional methods.

RESTRAINT

"Demand for refurbished equipment."

High costs associated with sequencing instruments remain a barrier, with 54% of small research centers preferring refurbished or second-hand sequencers due to budget limitations. The average upfront cost of high-throughput sequencing systems exceeds USD 1 million, excluding consumables and maintenance expenses. As a result, adoption among small- and mid-scale laboratories remains limited. Furthermore, 41% of labs cite high computational requirements as a challenge, as data analysis can require servers costing over USD 100,000 annually.

OPPORTUNITY

"Growth in personalized medicines."

The growing emphasis on personalized medicine is creating significant opportunities for NGS adoption. More than 60% of precision medicine programs worldwide rely on sequencing platforms for genetic profiling. In oncology, sequencing is applied in over 70% of personalized treatment decisions, while in rare diseases, sequencing enables diagnosis in over 50% of cases previously undiagnosed. Expanding applications in cardiology, neurology, and immunology further highlight the market’s potential. Governments worldwide are investing in personalized medicine initiatives, with over USD 2 billion allocated since 2021 for genome mapping and sequencing programs.

CHALLENGE

"Rising costs and expenditures."

Despite cost reductions, operational expenses remain a challenge. Sequencing consumables account for nearly 65% of the recurring costs per sequencing run, limiting accessibility for smaller institutions. Additionally, data storage presents a significant burden, as a single human genome generates 150 gigabytes of raw data, and large sequencing centers process petabytes annually. More than 38% of laboratories globally identify data management as a bottleneck, citing expenses of USD 30,000 annually for long-term storage solutions.

Next Generation Sequencing Market Segmentation

The Next Generation Sequencing market is segmented by type—SBS 52%, ion semiconductor 20%, nanopore 15%, SMRT 10%—and by applications, with biotechnology 65%, research 30%, hospitals 28%, and others 17%, highlighting diverse clinical, pharmaceutical, and genomic research adoption.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Ion Semiconductor Sequencing: Ion semiconductor sequencing captures 20% global usage, offering rapid targeted sequencing with results under 24 hours. Over 500 clinical labs deploy it for oncology diagnostics, providing cost-effective solutions for small-scale projects and routine mutation detection workflows worldwide.

Ion semiconductor sequencing market size is USD 4,744.91 million in 2025, representing 23% share of global NGS and a projected 18.88% CAGR for 2025–2034 across clinical and research applications.

Top 5 Major Dominant Countries in the Ion Semiconductor Segment

• USA totals USD 1,803.07 million in ion-sequencing, representing 38% of the ion market share with a projected 18.88% CAGR across 2025–2034 in diagnostics and labs.
• China records USD 1,043.88 million in ion-sequencing, representing 22% ion market share with a projected 18.88% CAGR for 2025–2034 across research and clinical adoption.
• Germany holds USD 569.39 million in ion-sequencing, representing 12% ion market share and projecting an 18.88% CAGR during 2025–2034 in clinical genomics.
• Japan reports USD 711.74 million in ion-sequencing, representing 15% ion market share with a projected 18.88% CAGR for 2025–2034 across hospitals and research centers.
• UK captures USD 379.59 million in ion-sequencing, representing 8% ion market share and forecasting an 18.88% CAGR for 2025–2034 across diagnostics and translational research.

Sequencing by Synthesis (SBS): Sequencing by synthesis leads with 52% adoption, enabling 1 billion reads per run. It dominates large-scale projects, transcriptomics, and exome sequencing. More than 65% of academic research centers and biopharmaceutical firms use SBS platforms for high-throughput genomic analysis.

Sequencing by the synthesis (SBS) market size is USD 10,727.63 million in 2025, holding 52% share of global NGS, with a projected 18.88% CAGR for 2025–2034.

Top 5 Major Dominant Countries in the SBS Segment

• USA accounts for USD 4,291.05 million in the SBS segment, representing 40% SBS share and a projected 18.88% CAGR for 2025–2034 globally, consistently annually.
• China records USD 1,930.97 million in SBS, representing 18% SBS share with a projected 18.88% CAGR across 2025–2034, reflecting rapid clinical and research uptake.
• Japan captures USD 1,287.32 million in SBS, representing 12% SBS share and projecting an 18.88% CAGR from 2025 through 2034 across clinical and research sectors.
• Germany accounts for USD 1,072.76 million in SBS, representing 10% SBS share with a projected 18.88% CAGR during 2025–2034 across diagnostics and research installations.
• UK holds USD 858.21 million in SBS, representing 8% SBS share and a projected 18.88% CAGR for 2025–2034 across academic, clinical, and commercial sequencing use.

Nanopore Sequencing: Nanopore sequencing accounts for 15% share, with over 15,000 portable sequencers deployed globally. Its capability to read DNA fragments exceeding 1 million base pairs supports structural variant research, infectious disease surveillance, and field-based real-time genomic sequencing applications worldwide.

Nanopore sequencing market size is USD 3,094.51 million in 2025, accounting for 15% share of global NGS and expecting a projected 18.88% CAGR for 2025–2034 across field and clinical applications.

Top 5 Major Dominant Countries in the Nanopore Segment

• UK leads nanopore with USD 928.35 million, representing 30% of the nanopore market and a projected 18.88% CAGR for 2025–2034 in portable and clinical sequencing uses.
• USA records USD 773.63 million in nanopore, representing 25% nanopore share with a projected 18.88% CAGR across 2025–2034 driven by research and point-of-care applications.
• China accounts for USD 618.90 million in nanopore, representing 20% nanopore share and projecting an 18.88% CAGR for 2025–2034 in surveillance and research deployment.
• Germany holds USD 371.34 million in nanopore, representing 12% nanopore share with a projected 18.88% CAGR for 2025–2034 in microbiology and clinical programs.
• Japan captures USD 247.56 million in nanopore, representing 8% nanopore share and projecting an 18.88% CAGR for 2025–2034 across hospitals and genomics centers.

Single-Molecule Real-Time (SMRT) Sequencing: SMRT sequencing holds 10% share, used extensively in microbiology and epigenomics. Over 25% of global epigenetic research utilizes SMRT for direct methylation detection. Its ability to generate long reads enhances genome assemblies and rare mutation identification.

Single-molecule real-time (SMRT) sequencing market size is USD 2,063.01 million in 2025, representing 10% global NGS share, with an 18.88% projected CAGR throughout 2025–2034 globally.

Top 5 Major Dominant Countries in the SMRT Segment

• USA captures USD 722.05 million in SMRT, representing 35% of SMRT market share with a projected 18.88% CAGR across 2025–2034 for complex genome and epigenetic studies.
• Japan records USD 515.75 million in SMRT, representing 25% SMRT share and projecting an 18.88% CAGR for 2025–2034 in advanced sequencing and research applications.
• China accounts for USD 309.45 million in SMRT, representing 15% SMRT share with a projected 18.88% CAGR during 2025–2034 across academic and clinical deployments.
• Germany holds USD 309.45 million in SMRT, representing 15% SMRT share and projecting an 18.88% CAGR for 2025–2034 in microbiome and structural genomics research.
• UK reports USD 206.30 million in SMRT, representing 10% SMRT share with a projected 18.88% CAGR for 2025–2034 in specialized genomic and epigenomics programs.

BY APPLICATION

Biotechnology and Pharmaceutical Companies: Over 65% of biotechnology and pharmaceutical companies use sequencing for drug discovery, vaccine development, and biomarker research. More than 500 active drug pipelines globally integrate NGS, accelerating development timelines and enabling targeted therapies through precision genetic profiling.

Biotechnology and Pharmaceutical Companies market size is USD 8,252.02 million in 2025, representing 40% application share, with a projected 18.88% CAGR across 2025–2034 in drug discovery and biomarker research.

Top 5 Major Dominant Countries in the Biotechnology and Pharmaceutical Companies Application

• USA accounts for USD 3,300.81 million in biotechnology application, representing 40% share of this segment with a projected 18.88% CAGR for 2025–2034 supporting drug development.
• China records USD 1,650.40 million in biotech application, representing 20% share with a projected 18.88% CAGR for 2025–2034 driven by growing R&D investment.
• UK contributes USD 990.24 million in biotech application, representing 12% share with a projected 18.88% CAGR for 2025–2034 across clinical trials and translational research.
• Germany holds USD 825.20 million in biotech application, representing 10% share and a projected 18.88% CAGR for 2025–2034 in pharmaceutical research and diagnostics partnerships.
• Japan provides USD 660.16 million in biotech application, representing 8% share with a projected 18.88% CAGR for 2025–2034 supporting precision therapeutics and genomics R&D.

Research Centres: Research centers account for 30% global usage, driven by over 800 genome sequencing projects. More than 70% of national genome programs worldwide depend on sequencing technologies, supporting population-scale studies and advancing basic science, disease biology, and genomic diversity mapping.

Research Centres market size is USD 5,157.52 million in 2025, representing 25% application share, with a projected 18.88% CAGR across 2025–2034 supporting population genomics and academic sequencing initiatives.

Top 5 Major Dominant Countries in the Research Centres Application

• USA contributes USD 1,805.13 million in research centre sequencing, representing 35% share of this application with a projected 18.88% CAGR for 2025–2034 across universities and institutes.
• China records USD 1,289.38 million for research centres, representing 25% share with a projected 18.88% CAGR for 2025–2034 driven by national genomics programs.
• UK holds USD 773.63 million in research centres, representing 15% share and a projected 18.88% CAGR for 2025–2034 across academic sequencing projects.
• Germany accounts for USD 773.63 million in research centres, representing 15% share with a projected 18.88% CAGR for 2025–2034 in institutional genomics infrastructure.
• Japan provides USD 515.75 million in research centres, representing 10% share with a projected 18.88% CAGR for 2025–2034 supporting advanced genome science.

Hospitals & Clinics: Hospitals and clinics represent 28% of sequencing adoption. More than 2,500 facilities globally apply NGS for oncology, rare disease, and prenatal testing. Over 1.2 million clinical samples are processed annually, strengthening precision medicine and patient-specific treatment strategies.

Hospitals & Clinics market size is USD 5,157.52 million in 2025, representing 25% application share, with a projected 18.88% CAGR across 2025–2034 for clinical diagnostics, oncology panels, and prenatal testing.

Top 5 Major Dominant Countries in the Hospitals & Clinics Application

• USA leads hospitals and clinics with USD 2,320.88 million, representing 45% share of this application and a projected 18.88% CAGR for 2025–2034 supporting clinical diagnostics.
• China reports USD 1,031.50 million in hospitals and clinics, representing 20% share with a projected 18.88% CAGR for 2025–2034 across diagnostic adoption.
• Germany contributes USD 773.63 million in hospitals and clinics, representing 15% share and a projected 18.88% CAGR for 2025–2034 in clinical genomics.
• UK records USD 515.75 million in hospitals and clinics, representing 10% share with a projected 18.88% CAGR for 2025–2034 in hospital-based testing.
• Japan provides USD 515.75 million for hospitals and clinics, representing 10% share with a projected 18.88% CAGR for 2025–2034 in precision medicine diagnostics.

Others: Public health and agricultural applications account for 17% usage. Over 40% of infectious disease surveillance initiatives integrate NGS for pathogen tracking, while agricultural genomics supports more than 200 crop improvement projects, boosting disease resistance and enhancing food security worldwide.

Others application market size is USD 2,063.01 million in 2025, representing 10% application share, with a projected 18.88% CAGR across 2025–2034 for public health surveillance, agriculture, and veterinary genomics.

Top 5 Major Dominant Countries in the Others Application

• USA records USD 618.90 million in others application, representing 30% share with a projected 18.88% CAGR for 2025–2034 across public health and agricultural genomics projects.
• China contributes USD 515.75 million in others, representing 25% share and a projected 18.88% CAGR for 2025–2034 in surveillance and crop genomics initiatives.
• UK holds USD 309.45 million in others application, representing 15% share with a projected 18.88% CAGR for 2025–2034 in epidemiology and environmental genomics.
• Germany provides USD 309.45 million in others, representing 15% share and a projected 18.88% CAGR for 2025–2034 focused on agricultural and microbiome research.
• Japan records USD 309.45 million in others application, representing 15% share and a projected 18.88% CAGR for 2025–2034 across veterinary and environmental genomics.

Next Generation Sequencing Market Regional Outlook

The global Next Generation Sequencing market is led by North America with 45% share, followed by Europe at 27%, Asia-Pacific at 22%, and Middle East & Africa at 6%, driven by genome projects, clinical diagnostics, and biotechnology investments.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

NORTH AMERICA

North America dominates the market with 45% share, supported by more than 1,200 sequencing-enabled facilities across the U.S. and Canada. Over 1.5 million genomes are sequenced annually in the region, with oncology accounting for 60% of applications and personalized medicine adoption steadily expanding.

North America market size is USD 9,283.53 million in 2025, holding 45% regional share of global NGS, with a projected 18.88% CAGR across 2025–2034 driven by clinical and research adoption.

North America - Major Dominant Countries in the “Next Generation Sequencing Market”

• USA represents USD 7,890.00 million in North America, accounting for 85% regional share with a projected 18.88% CAGR for 2025–2034 driven by hospital and research sequencing usage.
• Canada accounts for USD 742.68 million in North America, representing 8% regional share with a projected 18.88% CAGR for 2025–2034 across academic and clinical facilities.
• Mexico records USD 464.18 million in North America, representing 5% regional share with a projected 18.88% CAGR for 2025–2034 in public health and clinical genomics.
• Puerto Rico provides USD 92.84 million in North America, representing 1% regional share with a projected 18.88% CAGR for 2025–2034 supporting regional diagnostics.
• Bermuda contributes USD 92.84 million in North America, representing 1% regional share with a projected 18.88% CAGR for 2025–2034 in niche sequencing initiatives.

EUROPE

Europe contributes 27% share, led by the UK, Germany, and France, which together hold 65% of regional capacity. Over 500,000 genomes have been sequenced through national projects, with strong applications in rare disease research, infectious disease surveillance, and expanding precision medicine initiatives across academic and clinical institutions.

Europe market size is USD 5,570.12 million in 2025, holding 27% regional share of global NGS, with a projected 18.88% CAGR across 2025–2034 supported by national genome programs and clinical sequencing.

Europe - Major Dominant Countries in the “Next Generation Sequencing Market”

• UK contributes USD 1,671.04 million in Europe, representing 30% regional share with a projected 18.88% CAGR for 2025–2034 driven by public projects and clinical use.
• Germany accounts for USD 1,392.53 million in Europe, representing 25% regional share with a projected 18.88% CAGR for 2025–2034 across diagnostics and research centers.
• France records USD 835.52 million in Europe, representing 15% regional share and a projected 18.88% CAGR for 2025–2034 in national genomic initiatives.
• Italy holds USD 835.52 million in Europe, representing 15% regional share with a projected 18.88% CAGR for 2025–2034 across clinical and research installations.
• Spain provides USD 835.52 million in Europe, representing 15% regional share with a projected 18.88% CAGR for 2025–2034 in hospital and public health genomics.

ASIA-PACIFIC

Asia-Pacific accounts for 22% share, with China sequencing over 1 million genomes since 2020. Japan and South Korea are accelerating adoption in hospitals and research facilities, while India is expanding diagnostics capacity. The region benefits from government genome programs and strong investments in biotechnology and precision medicine.

Asia-Pacific market size is USD 4,538.61 million in 2025, holding 22% regional share of global NGS, with a projected 18.88% CAGR across 2025–2034 driven by national sequencing initiatives and rising clinical adoption.

Asia-Pacific - Major Dominant Countries in the “Next Generation Sequencing Market”

• China leads with USD 2,269.30 million in Asia-Pacific, representing 50% regional share and a projected 18.88% CAGR for 2025–2034 driven by large-scale sequencing programs.
• Japan contributes USD 907.72 million in Asia-Pacific, representing 20% regional share with a projected 18.88% CAGR for 2025–2034 across clinical genomics and research centers.
• India records USD 680.79 million in Asia-Pacific, representing 15% regional share and a projected 18.88% CAGR for 2025–2034 in diagnostics and public health projects.
• South Korea holds USD 453.86 million in Asia-Pacific, representing 10% regional share with a projected 18.88% CAGR for 2025–2034 in hospital and research deployments.
• Australia provides USD 226.93 million in Asia-Pacific, representing 5% regional share with a projected 18.88% CAGR for 2025–2034 across clinical and agricultural genomics.

MIDDLE EAST & AFRICA

Middle East & Africa represent 6% of global share, with Saudi Arabia and the UAE accounting for over 60% of regional sequencing capacity. Genome initiatives drive adoption in rare disease research and public health. Limited infrastructure outside key countries restricts expansion but growing investments support gradual development.

Middle East & Africa market size is USD 1,237.80 million in 2025, holding 6% regional share of global NGS, with a projected 18.88% CAGR across 2025–2034 driven by targeted national genome initiatives.

Middle East and Africa - Major Dominant Countries in the “Next Generation Sequencing Market”

• Saudi Arabia represents USD 432.23 million in MEA, accounting for 35% regional share with a projected 18.88% CAGR for 2025–2034 driven by national genomics programs.
• UAE contributes USD 309.45 million in MEA, representing 25% regional share with a projected 18.88% CAGR for 2025–2034 across clinical and public health sequencing.
• South Africa records USD 185.67 million in MEA, representing 15% regional share with a projected 18.88% CAGR for 2025–2034 in research and diagnostics.
• Egypt provides USD 185.67 million in MEA, representing 15% regional share with a projected 18.88% CAGR for 2025–2034 supporting public health genomics.
• Nigeria holds USD 123.78 million in MEA, representing 10% regional share with a projected 18.88% CAGR for 2025–2034 in surveillance and research programs.

List of Top Next Generation Sequencing Companies

• DNAnexus (US)
• Hamilton Company (US)
• BGI Group (China)
• Lucigen (US)
• Thermo Fisher Scientific, Inc. (US)
• GENEWIZ (US)
• Oxford Nanopore Technologies (UK)
• PerkinElmer Inc. (US)
• SciGenom Labs Pvt. Ltd. (India)
• Macrogen (South Korea)
• Takara Bio Inc. (Japan)
• DNASTAR, Inc. (US)
• QIAGEN (Netherlands)
• Becton Dickinson and Company (US)
• Zymo Research (US)
• Partek Incorporated (US)
• Tecan Trading AG (Switzerland)
• Lexogen GmbH (Austria)
• Danaher (US)
• Intrexon Bioinformatics GmbH (Germany)
• Agilent Technologies, Inc. (US)
• Illumina, Inc. (US)

Top Companies with Highest Share:

• Illumina, Inc. holds 48% global market share, dominating sequencing by synthesis platforms.
• Thermo Fisher Scientific, Inc. accounts for 24% share, with strong presence in research and clinical diagnostics.

Investment Analysis and Opportunities

Investments in the Next Generation Sequencing market are accelerating, with more than USD 4 billion in global funding directed toward genomics between 2020 and 2023. Governments in Asia-Pacific have allocated over USD 1.5 billion toward national genome mapping programs.

Opportunities lie in personalized medicine, where 60% of future clinical trials are expected to incorporate sequencing as a core technology. Infectious disease surveillance is another growth area, with over 100 countries integrating NGS into national health strategies.

New Product Development

Innovation in the Next Generation Sequencing market is accelerating, with manufacturers introducing advanced platforms and consumables. In 2023, Illumina launched upgraded sequencing systems capable of generating over 3 terabases of data per run, cutting sequencing time to less than 24 hours.

Thermo Fisher introduced new reagent kits reducing sequencing errors by 30%, improving accuracy for clinical applications. BGI launched automation solutions enabling parallel sequencing of 500 samples per batch, increasing throughput for population-scale studies.

Five Recent Developments

• In 2023, Illumina launched a new sequencing platform capable of 25% higher read accuracy compared to previous models.
• In 2023, Oxford Nanopore introduced an upgraded portable sequencer processing 3 gigabases of data per hour.
• In 2024, Thermo Fisher developed a reagent kit reducing sequencing costs by 20% per sample.
• In 2024, BGI deployed automated sequencing robots processing 1,000 samples simultaneously.
• In 2025, QIAGEN expanded cloud-based bioinformatics software, improving analysis speed by 40%.

Report Coverage of Next Generation Sequencing Market

The Next Generation Sequencing Market Report provides detailed insights into industry performance, growth trends, and technological innovations. Covering over 25 major countries, the report analyzes data from more than 1,500 companies, research centers, and hospitals deploying sequencing technologies.

The report highlights key drivers, restraints, opportunities, and challenges impacting the market. It examines the adoption of sequencing in over 10 clinical applications ranging from oncology and rare diseases to infectious disease surveillance and prenatal testing. Competitive analysis covers 22 major manufacturers with detailed insights into their market share, product portfolios, and strategic initiatives.

Next Generation Sequencing Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 24524.94 Million in 2026
Market Size Value By	USD 116311 Million by 2035
Growth Rate	CAGR of 18.88% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Ion semiconductor sequencing Sequencing by the synthesis (SBS) Nanopore sequencing Single-molecule real-time (SMRT) sequencing By Application : Biotechnology and Pharmaceutical Companies Research Centres Hospitals & Clinics Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample